(NASDAQ: AUPH) Aurinia Pharmaceuticals's forecast annual revenue growth rate of 34.38% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Aurinia Pharmaceuticals's revenue in 2024 is $175,513,000.On average, 4 Wall Street analysts forecast AUPH's revenue for 2024 to be $32,624,320,930, with the lowest AUPH revenue forecast at $31,338,669,025, and the highest AUPH revenue forecast at $33,668,461,171. On average, 4 Wall Street analysts forecast AUPH's revenue for 2025 to be $43,705,223,090, with the lowest AUPH revenue forecast at $39,104,642,845, and the highest AUPH revenue forecast at $49,154,131,126.
In 2026, AUPH is forecast to generate $64,309,349,495 in revenue, with the lowest revenue forecast at $59,206,511,763 and the highest revenue forecast at $69,412,187,227.